REFERENCES
- Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc.) 2003; 39(Suppl C)1–16, [CSA]
- Leonard J. P., Coleman M., Ketas J. C., et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 2004; 10(16)5327–5334, [INFOTRIEVE], [CROSSREF], [CSA]
- Leonard J. P., Coleman M., Ketas J., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 2005; 23(22)5044–5051, [INFOTRIEVE], [CROSSREF], [CSA]
- Mavromatis B., Cheson B. D. Monoclonal antibody therapy of chronic lymphocytic leukemia. J. Clin. Oncol. 2003; 21(9)1874–1881, [INFOTRIEVE], [CROSSREF], [CSA]
- Wierda W. G., Kipps T. J., Keating M. J. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J. Clin. Oncol. 2005; 23(26)6325–6332, [INFOTRIEVE], [CROSSREF], [CSA]
- Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983; 62(4)873–882, [INFOTRIEVE], [CSA]
- Hale G., Swirsky D. M., Hayhoe F. G., Waldmann H. Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med. 1983; 1(3)321–34, [INFOTRIEVE], [CSA]
- Hale G., Cobbold S. P., Waldmann H., Easter G., Matejtschuk P., Coombs R. R. Isolation of low-frequency class-switch variants from rat hybrid myelomas. J. Immunol. Methods. 1987; 103(1)59–67, [INFOTRIEVE], [CROSSREF], [CSA]
- Dyer M. J., Hale G., Hayhoe F. G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989; 73(6)1431–1439, [INFOTRIEVE], [CSA]
- Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 1988; 332(6162)323–327, [INFOTRIEVE], [CROSSREF], [CSA]
- James L. C., Hale G., Waldmann H., Bloomer A. C. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. J. Mol. Biol. 1999; 289(2)293–301, [INFOTRIEVE], [CROSSREF], [CSA]
- Keating M. J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002; 99(10)3554–3561, [INFOTRIEVE], [CROSSREF], [CSA]
- O'Brien S. M., Kantarjian H. M., Cortes J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 2001; 19(5)1414–1420, [INFOTRIEVE], [CSA]
- Keating M. J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005; 23(18)4079–4088, [INFOTRIEVE], [CROSSREF], [CSA]
- Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2005; 23(18)4070–4078, [INFOTRIEVE], [CROSSREF], [CSA]
- Keating M. J., O'Brien S., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002; 43(9)1755–1762, [INFOTRIEVE], [CROSSREF], [CSA]
- O'Brien S. M., Kantarjian H. M., Thomas D. A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98(12)2657–2663, [INFOTRIEVE], [CROSSREF], [CSA]
- Elter T., Borchmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J. Clin. Oncol. 2005; 23(28)7024–7031, [INFOTRIEVE], [CROSSREF], [CSA]
- Dearden C. E., Matutes E., Cazin B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98(6)1721–1726, [INFOTRIEVE], [CROSSREF], [CSA]
- Keating M. J., Cazin B., Coutre S., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol. 2002; 20(1)205–213, [INFOTRIEVE], [CROSSREF], [CSA]
- Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003; 101(11)4267–4272, [INFOTRIEVE], [CROSSREF], [CSA]
- Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004; 103(8)2920–2924, [INFOTRIEVE], [CROSSREF], [CSA]
- Thursky K. A., Worth L. J., Seymour J. F., Miles Prince H., Slavin M. A. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br. J. Haematol. 2006; 132(1)3–12, [INFOTRIEVE], [CROSSREF], [CSA]
- Keating M., Coutre S., Rai K., et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin. Lymphoma. 2004; 4(4)220–227, [INFOTRIEVE], [CSA]
- Ravandi F., O'Brien S. Alemtuzumab. Expert Rev. Anticancer Ther. 2005; 5(1)39–51, [INFOTRIEVE], [CROSSREF], [CSA]
- Xia M. Q., Hale G., Lifely M. R., et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J. 1993; 293(Pt 3)633–640, [INFOTRIEVE], [CSA]
- Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001; 3(3)137–143, [INFOTRIEVE], [CROSSREF], [CSA]
- Treumann A., Lifely M. R., Schneider P., Ferguson M. A. Primary structure of CD52. J. Biol. Chem. 1995; 270(11)6088–6099, [INFOTRIEVE], [CROSSREF], [CSA]
- Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 1998; 22(2)185–191, [INFOTRIEVE], [CROSSREF], [CSA]
- Isaacs J. D. The antiglobulin response to therapeutic antibodies. Semin. Immunol. 1990; 2(6)449–456, [INFOTRIEVE], [CSA]
- Hale G., Rebello P., Brettman L. R., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004; 104(4)948–955, [INFOTRIEVE], [CROSSREF], [CSA]
- Cheetham G. M., Hale G., Waldmann H., Bloomer A. C. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J. Mol. Biol. 1998; 284(1)85–99, [INFOTRIEVE], [CROSSREF], [CSA]
- Rowan W., Tite J., Topley P., Brett S. J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology. 1998; 95(3)427–436, [INFOTRIEVE], [CROSSREF], [CSA]
- Nuckel H., Frey U. H., Roth A., Duhrsen U., Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur. J. Pharmacol. 2005; 514(2–3)217–224, [INFOTRIEVE], [CSA]
- Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3)754–758, [INFOTRIEVE], [CROSSREF], [CSA]
- Farag S. S., Flinn I. W., Modali R., Lehman T. A., Young D., Byrd J. C. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004; 103(4)1472–1474, [INFOTRIEVE], [CROSSREF], [CSA]
- Weng W. K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003; 21(21)3940–3947, [INFOTRIEVE], [CROSSREF], [CSA]
- Lin T. S., Flinn I. W., Modali R., et al. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005; 105(1)289–291, [INFOTRIEVE], [CROSSREF], [CSA]
- Rebello P., Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J. Immunol. Methods. 2002; 260(1–2)285–302, [INFOTRIEVE], [CROSSREF], [CSA]
- Jilani I., Keating M., Giles F. J., O'Brien S., Kantarjian H M, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res. 2004; 28(12)1255–1262, [INFOTRIEVE], [CROSSREF], [CSA]
- Rebello P., Cwynarski K., Varughese M., Eades A., Apperley J. F., Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy. 2001; 3(4)261–267, [INFOTRIEVE], [CROSSREF], [CSA]
- Osterborg A., Dyer M. J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 1997; 15(4)1567–1574, [INFOTRIEVE], [CSA]
- Rai K. R., Freter C. E., Mercier R. J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 2002; 20(18)3891–3897, [INFOTRIEVE], [CROSSREF], [CSA]
- Osterborg A., Fassas A. S., Anagnostopoulos A., Dyer M. J., Catovsky D., Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 1996; 93(1)151–153, [INFOTRIEVE], [CROSSREF], [CSA]
- Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002; 100(3)768–773, [INFOTRIEVE], [CROSSREF], [CSA]
- Wendtner C. M., Ritgen M., Schweighofer C. D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL. Study Group (GCLLSG). Leukemia. 2004; 18(6)1093–1101, [INFOTRIEVE], [CROSSREF], [CSA]
- Montillo M., Cafro A. M., Tedeschi A., et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002; 87(7)695–700, discussion[INFOTRIEVE], [CSA]
- Montillo M., Schinkoethe T., Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest. 2005; 23(6)488–496, [INFOTRIEVE], [CROSSREF], [CSA]
- Rai K., Byrd J., Peterson B. L., Larson R. A. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukamia Group B (CALGB) study 19901. Blood 2002; 100(11)205a, [CSA]
- Rai K. R., Byrd J. C., Peterson B., Gautier M., Larson R A. Subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901. Blood. 2003; 102(11)676a, [CSA]
- Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 2005; 23(13)2971–2979, [INFOTRIEVE], [CSA]
- Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995; 85(6)1580–1589, [INFOTRIEVE], [CSA]
- Cordone I., Masi S., Mauro F. R., et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998; 91(11)4342–4349, [INFOTRIEVE], [CSA]
- Stilgenbauer S., Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. 2002; 347(6)452–453, [INFOTRIEVE], [CROSSREF], [CSA]
- Lozanski G., Heerema N. A., Flinn I. W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004; 103(9)3278–3281, [INFOTRIEVE], [CROSSREF], [CSA]
- Faderl S., Coutre S., Byrd J. C., et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia. 2005; 19(12)2147–2152, [INFOTRIEVE], [CROSSREF], [CSA]
- Pawson R., Dyer M. J., Barge R., et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. 1997; 15(7)2667–2672, [INFOTRIEVE], [CSA]
- Lundin J., Osterborg A., Brittinger G., et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J. Clin. Oncol. 1998; 16(10)3257–3263, [INFOTRIEVE], [CSA]
- Ferrajoli A., O'Brien S. M., Cortes J. E., et al. Phase II. study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003; 98(4)773–778, [INFOTRIEVE], [CROSSREF], [CSA]
- Faderl S., Thomas D. A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101(9)3413–3415, [INFOTRIEVE], [CROSSREF], [CSA]
- Quigley M. M., Bethel K. J., Sharpe R. W., Saven A. CD52 expression in hairy cell leukemia. Am. J. Hematol. 2003; 74(4)227–230, [INFOTRIEVE], [CROSSREF], [CSA]
- Jordan M. B., McClain K. L., Yan X., Hicks J., Jaffe R. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005; 44(3)251–254, [INFOTRIEVE], [CROSSREF], [CSA]
- Sefcick A., Sowter D., DasGupta E., Russell N. H., Byrne J. L. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br. J. Haematol. 2004; 124(4)558–559, [INFOTRIEVE], [CROSSREF], [CSA]
- Rosenblum M. D., LaBelle J. L., Chang C. C., Margolis D. A., Schauer D. W., Vesole D. H. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood. 2004; 103(5)1969–1971, [INFOTRIEVE], [CROSSREF], [CSA]
- Ravandi F., Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk. Res. 2006; 30(1)103–105, [INFOTRIEVE], [CROSSREF], [CSA]
- Mone A., Puhalla S., Whitman S., et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-alpha-refractory adult T-cell leukemia. Blood. 2005; 106(10)3380–3382, [INFOTRIEVE], [CROSSREF], [CSA]
- Kumar S., Kimlinger T. K., Lust J. A., Donovan K., Witzig T. E. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood. 2003; 102(3)1075–1077, [INFOTRIEVE], [CROSSREF], [CSA]
- Lin P., Owens R., Tricot G., Wilson C. S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 2004; 121(4)482–488, [INFOTRIEVE], [CROSSREF], [CSA]
- Owen R. G., Hillmen P., Rawstron A. C. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin. Lymphoma. 2005; 5(4)278–281, [INFOTRIEVE], [CSA]
- Westermann J., Maschmeyer G., van Lessen A., Dorken B., Pezzutto A. CD52 is not a promising immunotherapy target for most patients with multiple myeloma. Int. J. Hematol. 2005; 82(3)248–250, [INFOTRIEVE], [CROSSREF], [CSA]
- Rawstron A. C., Kennedy B., Moreton P., et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 2004; 103(6)2027–2031, [INFOTRIEVE], [CROSSREF], [CSA]
- Wierda W. G., O'Brien S., Ferrajoli A., et al. Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL. Blood. 2005; 106(11), Abstract 719[CSA]
- Ravandi-Kashani F., Kantarjian H., Verstovsek S., et al. Combined Therapy with Alemtuzumab and Pentostatin Is Feasible and Effective in T- Lymphoproliferative Disorders. Blood. 2005; 106(11), Abstract 5024[CSA]